Cargando…

DNA Methylation Aberrant in Atherosclerosis

Atherosclerosis (AS) is a pathological process involving lipid oxidation, immune system activation, and endothelial dysfunction. The activated immune system could lead to inflammation and oxidative stress. Risk factors like aging and hyperhomocysteinemia also promote the progression of AS. Epigeneti...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Yao, Chen, Danian, Xu, Tingting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927809/
https://www.ncbi.nlm.nih.gov/pubmed/35308237
http://dx.doi.org/10.3389/fphar.2022.815977
_version_ 1784670526358159360
author Dai, Yao
Chen, Danian
Xu, Tingting
author_facet Dai, Yao
Chen, Danian
Xu, Tingting
author_sort Dai, Yao
collection PubMed
description Atherosclerosis (AS) is a pathological process involving lipid oxidation, immune system activation, and endothelial dysfunction. The activated immune system could lead to inflammation and oxidative stress. Risk factors like aging and hyperhomocysteinemia also promote the progression of AS. Epigenetic modifications, including DNA methylation, histone modification, and non-coding RNA, are involved in the modulation of genes between the environment and AS formation. DNA methylation is one of the most important epigenetic mechanisms in the pathogenesis of AS. However, the relationship between the progression of AS and DNA methylation is not completely understood. This review will discuss the abnormal changes of DNA methylation in AS, including genome-wide hypermethylation dominating in AS with an increase of age, hypermethylation links with methyl supply and generating hyperhomocysteinemia, and the influence of oxidative stress with the demethylation process by interfering with the hydroxyl-methylation of TET proteins. The review will also summarize the current status of epigenetic treatment, which may provide new direction and potential therapeutic targets for AS.
format Online
Article
Text
id pubmed-8927809
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89278092022-03-18 DNA Methylation Aberrant in Atherosclerosis Dai, Yao Chen, Danian Xu, Tingting Front Pharmacol Pharmacology Atherosclerosis (AS) is a pathological process involving lipid oxidation, immune system activation, and endothelial dysfunction. The activated immune system could lead to inflammation and oxidative stress. Risk factors like aging and hyperhomocysteinemia also promote the progression of AS. Epigenetic modifications, including DNA methylation, histone modification, and non-coding RNA, are involved in the modulation of genes between the environment and AS formation. DNA methylation is one of the most important epigenetic mechanisms in the pathogenesis of AS. However, the relationship between the progression of AS and DNA methylation is not completely understood. This review will discuss the abnormal changes of DNA methylation in AS, including genome-wide hypermethylation dominating in AS with an increase of age, hypermethylation links with methyl supply and generating hyperhomocysteinemia, and the influence of oxidative stress with the demethylation process by interfering with the hydroxyl-methylation of TET proteins. The review will also summarize the current status of epigenetic treatment, which may provide new direction and potential therapeutic targets for AS. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8927809/ /pubmed/35308237 http://dx.doi.org/10.3389/fphar.2022.815977 Text en Copyright © 2022 Dai, Chen and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Dai, Yao
Chen, Danian
Xu, Tingting
DNA Methylation Aberrant in Atherosclerosis
title DNA Methylation Aberrant in Atherosclerosis
title_full DNA Methylation Aberrant in Atherosclerosis
title_fullStr DNA Methylation Aberrant in Atherosclerosis
title_full_unstemmed DNA Methylation Aberrant in Atherosclerosis
title_short DNA Methylation Aberrant in Atherosclerosis
title_sort dna methylation aberrant in atherosclerosis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927809/
https://www.ncbi.nlm.nih.gov/pubmed/35308237
http://dx.doi.org/10.3389/fphar.2022.815977
work_keys_str_mv AT daiyao dnamethylationaberrantinatherosclerosis
AT chendanian dnamethylationaberrantinatherosclerosis
AT xutingting dnamethylationaberrantinatherosclerosis